Compare Amgen's income of 17bn to Johnson and Johnson 67bn and the thirteen major pharmaceutical companies in between. What is it going to cost those 15 companies if they don't win Partry's seven year patents as well as the R&D for the other products.
A lot less than paying overs for every small bio company with potential. PAB may well be a takeover target one day but not where they are currently at in their development.
takeover, page-40
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6.022K | 2.007M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 24652453 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 25089307 | 16 |
View Market Depth
| Last trade - 15.21pm 10/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |